Digest Network Come funziona
Network
/
Società
In
Non verificato

Incyte

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

87 comunicati stampa

Guarda tutti i comunicati
05/01/2026
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
Fonte
Incyte
Emittente
Business Wire
1.00
0
22/12/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fonte
Incyte
Emittente
Business Wire
1.00
0
22/12/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
Fonte
Incyte
Emittente
Business Wire
1.00
0
18/12/2025
Eventi
Web e Social Network
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Incyte to Present at Upcoming Investor Conference
Fonte
Incyte
Emittente
Business Wire
1.00
0
18/12/2025
Eventi
Web e Social Network
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Incyte to Present at Upcoming Investor Conference
Fonte
Incyte
Emittente
Business Wire
1.00
0
17/12/2025
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fonte
Incyte
Emittente
Business Wire
1.00
0
12/12/2025
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Incyte Announces Change to its Board of Directors
Fonte
Incyte
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Fonte
Incyte
Emittente
Business Wire
1.00
0
07/12/2025
Web e Social Network
Telefonia e Varie
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
Fonte
Incyte
Emittente
Business Wire
1.00
0
07/12/2025
Eventi
Industria
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
Fonte
Incyte
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0